Correlation between Cyclin D1, p53, Bcl-2 Protein Expression and Prognosis in Primary, Resected Stage IIIA Non-Small Cell Lung Cancer (NSCLC)

완전 절제된 제IIIA기 비소세포폐암에서 Cyclin D1, p53, Bcl-2 단백질 발현의 의의

  • 정경영 (연세대학교 의과대학 흉부외과학교실) ;
  • 양우익 (연세대학교 의과대학 흉부외과학교실)
  • Published : 1998.12.01

Abstract

Background: Lung cancer formation is a multistage process involving activation of protooncogene and inactivation of tumor suppressor genes. We evaluate the significance of cyclin D1, p53, bcl-2 gene mutations in patients with curatively resected stage IIIA non-small cell lung cancer(NSCLC). Material and Method: One hundred consecutive cases of stage IIIA lung cancers from patients operated on curatvely between 1990 and 1995 for which adequate paraffin blocks and clinical history were available. Immunohistochemical studies were performed on the representative tissue sections from each case by the labelled streptovidin- biotin method. Sections for cyclin D1, p53, Bcl-2 immunostaining were pretreated in a microwave oven for 10 to 20 minutes in citrate buffer before immunostaining. The overnight incubation with NCL-cyclin D1-GM for cyclin D1, with clone DO-7 for p53, with clone 124 for bcl-2 was done. Mean follow-up was 24.1 months (range 2-84 months) after operation. Result: One hundred cases of lung cancers were composed of 56 cases of squamous cell carcinoma, 37 cases of adenocarcinoma, 5 cases of adenosquamous cell carcinoma, and 2 cases of large cell carcinoma. The 5-year survival was 32.1%. The positive expression rate of cyclin D1 was 35%, p53 was 56%, and bcl-2 was 17%. But there were no correlation between cyclin D1, p53, Bcl-2 protein expression and survival. Conclusion: These observation indicate that cyclin D1, p53, bcl-2 protein overexpression might be implicated in the oncogenesis of non-small cell lung carcinomas but they have no usefulness as a prognostic marker.

연구목적: 폐암은 protooncogene의 활성화와 종양억제유전인자(tumor suppressor gene)의 비활성화 등 다단 과정에 의하여 발생한다. 치료목적의 완전 절제가 가능하였던 제 IIIA기 비소세포폐암 환자에서 cyclin D1, p53, bcl-2 gene의 변이가 폐암에 미치는 영향을 조사하고자 하였다. 대상 및 방법: 1990년부터 1995년까지 연세의료원에서 치료목적의 완전절제가 가능하였던 stageIIIA 비소세포폐암 환자 100명의 paraffin block과 임상기록을 이용하였다. 각 환자의 조직절편을 labelled streptavidin-biotin method로 immunohistochemical 염색하였고 cyclin D1, p53, Bcl-2 immunostaining을 위한 조직절편들은 immunostaining하기 전 citrate buffer 내에서 10분에서 20분간 microwave oven으로 전처치한 후 cyclin D1은 NCL-cyclin D1-GM으로 p53는 lone DO-7으로 bcl-2는 clone 124로 overnight incubation하였다. 수술 후 평균 추적조사기간은 24.1 개월(range; 2∼84 개월)이었다. 결과: 100예의 폐암 중 56예가 편평상피세포암, 37예가 선암, 5예가 adenosquamous cell carcinoma, 2예가 대세포암이었고 수술 후 5년 생존율은 32.1%이었다. cyclin D1의 양성율은 35 %, p53는 56 %, bcl-2는 17 %였으나 cyclin D1, p53, Bcl-2 단백질 양성 발현과 생존율과의 상관관계는 없었다. 결론: 연구결과 cyclin D1, p53, Bcl-2 단백질 양성 발현이 비소세포폐암 발생기전과 연관되어 있으나 수술 후 예후인자로서는 부적당한 것으로 판단되었다.

Keywords

References

  1. Yonsei Med J v.37 Cyclin D1 Protein Expression in Lung Cancer Yang WI;Chung KY;Shin DH(et al.)
  2. Principles and practice of oncology(4th ed) Cancer of the lung non-small cell lung cancer Ginsberg J;Kris MG;Amstrong JG;de Vita Jr VT;Heliman S;Rosenberg SA
  3. Lung cancer: Principles and Practice Molecular Biology overview Minna JD;Pass HI;Mitchell JB;Johnson DH;Turrist AT
  4. Chest v.109 Oncogenes and antioncogenes in lung tumorigenesis Giaccone G
  5. Proc Natl Acad Sci USA v.91 Function of a human cyclin gene as an oncogene Hinds PW;Dowdy SF;Eaton EN(et al.)
  6. Cancer v.66 Cyclins and cancer Hunter T;Pinls J
  7. Cancer v.74 PRAD-1(CCND1)/cyclinD1 oncogene amplification in primary head and neck squamous cell exarcinoma Callender T;El-Naggar AK;Lee MS(et al.)
  8. Cancer Cells v.3 Chromosome 11q13 abnormalities in human cancers Lammie G;Peters G
  9. Oncogene v.8 Expression and amplification of cyclin genes in human breast cancer Buckley MF;Sweeney KJF;Hamilton JA(et al.)
  10. Br J cancer v.73 Prognostic significance of CCND1 (cyclin D1) over expression in primary resected non-small-cell lung cancer Betticher DC;Heighway J;Hasleton PS(et al.)